310 related articles for article (PubMed ID: 35203272)
1. Potential Therapeutic Effects of PPAR Ligands in Glioblastoma.
Basilotta R; Lanza M; Casili G; Chisari G; Munao S; Colarossi L; Cucinotta L; Campolo M; Esposito E; Paterniti I
Cells; 2022 Feb; 11(4):. PubMed ID: 35203272
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors.
Strakova N; Ehrmann J; Bartos J; Malikova J; Dolezel J; Kolar Z
Neoplasma; 2005; 52(2):126-36. PubMed ID: 15800711
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review.
Grygiel-Górniak B
Nutr J; 2014 Feb; 13():17. PubMed ID: 24524207
[TBL] [Abstract][Full Text] [Related]
5. The Journey of Thiazolidinediones as Modulators of PPARs for the Management of Diabetes: A Current Perspective.
Ahsan W
Curr Pharm Des; 2019; 25(23):2540-2554. PubMed ID: 31333088
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial dysfunction by synthetic ligands of peroxisome proliferator activated receptors (PPARs).
Scatena R; Martorana GE; Bottoni P; Giardina B
IUBMB Life; 2004 Aug; 56(8):477-82. PubMed ID: 15545227
[TBL] [Abstract][Full Text] [Related]
7. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
Huang TH; Roufogalis BD
Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
[TBL] [Abstract][Full Text] [Related]
8. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
Michalik L; Auwerx J; Berger JP; Chatterjee VK; Glass CK; Gonzalez FJ; Grimaldi PA; Kadowaki T; Lazar MA; O'Rahilly S; Palmer CN; Plutzky J; Reddy JK; Spiegelman BM; Staels B; Wahli W
Pharmacol Rev; 2006 Dec; 58(4):726-41. PubMed ID: 17132851
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present).
Takada I; Makishima M
Expert Opin Ther Pat; 2020 Jan; 30(1):1-13. PubMed ID: 31825687
[No Abstract] [Full Text] [Related]
10. Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases.
Takano H; Hasegawa H; Zou Y; Komuro I
Curr Pharm Des; 2004; 10(22):2779-86. PubMed ID: 15320743
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists.
Kapadia R; Yi JH; Vemuganti R
Front Biosci; 2008 Jan; 13():1813-26. PubMed ID: 17981670
[TBL] [Abstract][Full Text] [Related]
12. Experimental approaches to study PPAR gamma agonists as antidiabetic drugs.
Vázquez M; Silvestre JS; Prous JR
Methods Find Exp Clin Pharmacol; 2002 Oct; 24(8):515-23. PubMed ID: 12500431
[TBL] [Abstract][Full Text] [Related]
13. Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure.
Thiemermann C
Br J Pharmacol; 2004 Jul; 142(6):1049-51. PubMed ID: 15303252
[TBL] [Abstract][Full Text] [Related]
14. The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs).
Staels B; Schoonjans K; Fruchart JC; Auwerx J
Biochimie; 1997; 79(2-3):95-9. PubMed ID: 9209702
[TBL] [Abstract][Full Text] [Related]
15. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
Mansour M
Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
[TBL] [Abstract][Full Text] [Related]
16. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice.
Derosa G; Sahebkar A; Maffioli P
J Cell Physiol; 2018 Jan; 233(1):153-161. PubMed ID: 28098353
[TBL] [Abstract][Full Text] [Related]
17. Thiazolidinediones as antidiabetic agents: A critical review.
Nanjan MJ; Mohammed M; Prashantha Kumar BR; Chandrasekar MJN
Bioorg Chem; 2018 Apr; 77():548-567. PubMed ID: 29475164
[TBL] [Abstract][Full Text] [Related]
18. A new insight into the treatment of diabetes by means of pan PPAR agonists.
Chandra A; Kaur P; Sahu SK; Mittal A
Chem Biol Drug Des; 2022 Dec; 100(6):947-967. PubMed ID: 34990085
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer.
Wagner N; Wagner KD
Cells; 2022 Aug; 11(15):. PubMed ID: 35954274
[TBL] [Abstract][Full Text] [Related]
20. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity.
Ferré P
Diabetes; 2004 Feb; 53 Suppl 1():S43-50. PubMed ID: 14749265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
